Sutro Biopharma(US:STRO)2022-04-13 16:21STRO-002 Clinical Trial Results and Strategy - In the dose expansion cohort of the STRO-002 trial for ovarian cancer, an overall response rate (ORR) of 333% was observed in all 33 evaluable patients[52] - A higher ORR of 471% was seen in patients starting at the 52 mg/kg dose level[52] - Exploratory analysis suggests that a tumor proportion score (TPS) > 25% correlated with higher response, demonstrating a 400% ORR (10 out of 25 patients)[68, 76] and 538% ORR (7/13) in patients at the 52 mg/kg starting dose[76] - 855% of treatment-emergent adverse events (TEAEs) were Grade 1-2, indicating a manageable safety profile[72, 76] - The company plans to initiate a pivotal trial in ovarian cancer by year-end 2022 and has dosed the first patient in the endometrial cancer cohort in November 2021[13] STRO-001 Clinical Trial and Development - STRO-001 is undergoing Phase 1 dose escalation studies, with the latest reported dose levels at 50 mg/kg in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) cohorts[91] - In the NHL cohort, the median number of prior therapies was 5 (range 1-12)[94] - Interim data from the NHL cohort showed partial responses in two DLBCL patients who had progressed on CAR-T therapy[96] Financial Position and Partnerships - The company reported $2295 million in cash, cash equivalents, and marketable securities as of December 31, 2021[99] - Projected cash runway extends into the second half of 2023, based on current business plans and assumptions[99] - Funding received from collaborators totaled approximately $446 million through December 31, 2021[99]